Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aurobindo Accelerates Biosimilars Efforts With Second Filing

As Company Makes Seven Drug Launches in Q3 FY22

Executive Summary

Aurobindo has filed for its second oncology biosimilar with the EMA in January 2022, as the company remains on track to develop its biosimilars portfolio in both oncology and immunology segments. The company has also launched seven products, including four injectables, in its financial third quarter ended 31 December 2021.

You may also be interested in...



What’s Next? Five Things To Look Out For In April

In the month ahead, Japanese firms are set to be hit with further price cuts to their generics, while Eagle Pharmaceuticals will throw off the restraints for its Pemfexy (pemetrexed) 505(b)(2) version of Eli Lilly’s Alimta.

Aurobindo Seeks To Boost India Business With Veritaz Acquisition

Aurobindo is looking to grow its business in India by acquiring Veritaz’s domestic formulations operations in a $22.4m slump sale.

Aurobindo’s CuraTeQ Expands Biosimilars Deal With Orion For Baltic Countries

Aurobindo’s CuraTeQ Biologics has expanded its biosimilar distribution agreement with Finnish Player Orion. After covering the Nordics, Austria, Hungary and Slovenia, the partnering companies have decided to expand to the Baltic countries, with launches slated for between 2023 and 2026.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB151679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel